A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Singledose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion of AZD1305 in Patients Undergoing an Invasive Electrophysiological Procedure.

Trial Profile

A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Singledose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion of AZD1305 in Patients Undergoing an Invasive Electrophysiological Procedure.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2015

At a glance

  • Drugs AZD 1305 (Primary)
  • Indications Atrial flutter
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 01 Nov 2012 Planned number of patients changed from 48 to 64.
    • 23 Jan 2009 Status changed from recruiting to completed, according to clinicaltrials.gov.
    • 18 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top